NasdaqGS:LEGNBiotechs
Legend Biotech (NasdaqGS:LEGN): Reassessing Valuation After New Long-Term CARVYKTI Data from CARTITUDE Studies
Legend Biotech (LEGN) just released fresh long term data on its flagship CAR T therapy CARVYKTI from the CARTITUDE program in hard to treat multiple myeloma, clarifying its profile for durability, safety, and potential future revenue.
See our latest analysis for Legend Biotech.
Despite today’s positive CARVYKTI update, Legend Biotech’s 30 day share price return of minus 21.71 percent and one year total shareholder return of minus 35.68 percent show sentiment has been weak, but the 3.01...